Graves' disease is the most common cause of hyperthyroidism and is often managed with radioactive iodine (RAI) therapy. With current dosing schemes, the vast majority of patients develops permanent post-RAI hypothyroidism and are placed on life-long levothyroxine therapy.
Introduction
Although not nearly as common as hypothyroidism, the overall prevalence of hyperthyroidism is still substantial at approximately 0.2%, and in women the prevalence ranges between 0.5% and 2%. 1 The vast majority of the time Graves' disease is the underlying etiology, representing 60%-80% of cases. 2 For decades the management options for Graves' disease have remained unchanged, consisting of either anti-thyroid drugs (ATD), radioactive iodine (RAI), or surgery.
Though surgery has continued to be the least commonly employed management, the proportion of patients managed with ATD or RAI varies by country. 3 Additionally, there appears to be a trend toward less frequent use of RAI in both North America and Europe based on surveys of endocrinologists 3 and ATD prescription trends . 4 Despite these changing trends, RAI remains the most commonly employed treatment of Graves' disease in the United States.
With currently employed dosing regimens, hypothyroidism is the most common outcome after RAI therapy for Graves' disease, occurring in up to 80% of patients, the vast majority within the first 6 months. 5 This is in contrast with the typical outcome of RAI therapy in the treatment of autonomously functioning thyroid nodular disease in which many patients will become and remain euthyroid after treatment. Though most patients with Graves' disease develop permanent post-RAI hypothyroidism, there is a small subset (2-5%) in whom the hypothyroidism is transient, which can confound the typically straightforward management of hypothyroidism. 5, 6 Though the possibility of post-RAI transient hypothyroidism has been described in several older reports [7] [8] [9] and a recent comprehensive review, 6 it is not widely appreciated. Furthermore, it can sometimes be difficult to distinguish transient from permanent post-RAI hypothyroidism. Lastly, transient post-RAI hypothyroidism can, on recovery, be followed by either euthyroidism and Linking powered by eXtyles eventual progression to permanent hypothyroidism without further therapy or persistent hyperthyroidism requiring a second dose of RAI therapy or anti-thyroid medication. 6 We herein present five cases of transient post-RAI hypothyroidism highlighting the two possible eventual outcomes. In each case an unusual or unexpected pattern of laboratory data occurred after the initiation of L-thyroxine therapy for post-RAI hypothyroidism. In four of these cases this occurred very shortly after replacement therapy was initiated, perhaps making it a bit more recognizable, but in one case the transient nature of hypothyroidism did not reveal itself for over a year. These cases highlight the importance of remaining aware of the possibility of the usual or even protracted transient post-RAI hypothyroidism, so that timely, appropriate management of the patient can occur.
Case 1.
A 42-year-old woman presented elsewhere with symptoms of tremors, palpitations, heat intolerance, and sleep disturbance in January 2000. At presentation, her physical examination was not well documented in the outside records. Her thyroid stimulating hormone (TSH) was < 0.01 mIU/mL (normal: 0.40-5.70), and a 24-hour radioactive iodine uptake (RAIU) was dramatically elevated at 89.2%, indicative of Graves' disease. She received 7 mCi (259 MBq) of I-131 for treatment in February. Three months later, she was subjectively and biochemically hypothyroid with a TSH of 14.29 mIU/mL and a free T4 of < 0.5 ng/dL (normal: 0.8-1.8). Levothyroxine therapy was begun, and after several minor dose alterations, a stable dose of 0.1 mg daily (1.5 mcg/kg/day) was achieved. In September 2001, 15 months later, during an evaluation for abdominal pain, her TSH was suppressed to < 0.01 mIU/mL with a free T4 elevated to 1.9
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TSH < 0.05 mIU/mL, free T3 3.8 pg/mL and free T4 1.5 ng/dL. Graves' antibodies were positive with a TSH receptor antibody at 44 (normal: < 16). Levo-thyroxine was discontinued, and eventually his thyroid function tests normalized 5 months later without further treatment (TSH 0.38 mIU/mL and free T4 0.6 ng/dL). In November 2008, his TSH remained normal at 2.69 mIU/lL. He was lost to follow-up until July 2010,when his TSH had risen to 30.14 mIU/mL.
Levo-thyroxine was re-initiated at 0.088 mg daily, and the patient's TSH remained normal on that dose as of October 2013.
Case 4.
In and free T4 4.6 ng/dL [normal: 0.8-1.9]), and a thyroid uptake and scan revealed a homogenously elevated uptake of 75% at 24 hours consistent with Graves' disease. She denied symptoms of thyrotoxicosis. On examination, however, she was tachycardic, had mild signs of Graves' eye disease, a small, firm symmetric goiter, fine upper extremity tremor, and hyperreflexia. She received 12.5 mCi (463 MBq) of I-131 for treatment. Three months after RAI therapy she was clinically hypothyroid, complaining of significant fatigue and having gained 9 kg. Her TSH was < 0.03 mIU/mL with a low free T4 of 0.6 ng/dL. She was felt to indeed be hypothyroid, and her TSH was deemed to be lagging behind in its predicted rise related to her previous hyperthyroidism. She was started on L-thyroxine 0.125 mg daily (1.1 mcg/kg/day). Six weeks later she felt improved but, as her TSH was < 0.03 mIU/mL, her dose was decreased. 
Case 5.
In September 2007, a 31 year-old woman presented with several months of symptoms consistent with hyperthyroidism including tremor, anxiety, sleep disturbance, and palpitations. Physical examination revealed a heart rate of 112 beats per minute and a fine bilateral upper extremity tremor. She had a firm, diffusely enlarged thyroid gland with a soft bruit. Her laboratory data revealed a TSH of < 0.05 mIU/mL (normal: 0.35-4.50), a free T3 of 22.6 pg/mL (normal: 2.1-4.1), and a free T4 of 4.7 ng/dL (normal: 0.6-1.9). Her thyroid uptake was elevated at 62% in a diffuse pattern, confirming Graves' disease. It was recommended that RAI therapy be pursued, but she preferred to utilize anti-thyroid drug therapy, so propylthiouracil (PTU) 100 mg three times daily was begun. Despite the inability to completely normalize her thyroid function tests, the patient refused to undergo I-131 therapy. She remained on PTU, following up with her This form of stunning is different from that seen immediately after RAI administration where iodide transport is reduced, 11 or from the effect of propylthiouracil on thyroidal uptake of RAI when used within 2 weeks of administration of RAI. 12, 13 Both of the latter are concerns regarding the effectiveness of RAI subsequently, rather than on transient hypothyroidism at 3 months, although this does not preclude a flow on effect too.
The incidence of transient hypothyroidism due to prolonged stunning after RAI therapy (seen in cases 1 to 3 above and summarized in while one suggests younger age, larger goiters, and pretreatment with PTU to be predictive.
Also, failure of I-131 treatment may be more common in men versus women. 14, 15 Note is made that two of these three cases of thyroid stunning were male, and we may speculate perhaps this recovered. The potential for thyroid antibodies to play such a role has been described by Yoshida et al. 16 who reported on fluctuating levels of TSI and TBII after RAI therapy, which had some correlation to fluctuating thyroid function. TSH receptor antibody levels were not drawn in this patient, so this possibility cannot be proven though, again, it certainly seems plausible. This patient then progressed to euthyroidism after resolution of the protracted but transient hypothyroid state. Such euthyroidism after radioiodine depends on the dose administered, with lower doses tending to allow prolonged periods of euthyroidism as opposed to higher doses where permanent hypothyroidism ensues quickly. This dose-dependent effect of radioiodine is due to a direct cellular toxicity of radiation, but once euthyroidism ensues, hypothyroidism is inevitable because of the persistent effect of radioiodine due to continuing mitotic cell death, which is independent of dose. 17 Thus, the lower dose in case 1 rendered her euthyroid for a prolonged period before permanent hypothyroidism ensued, but it should be kept in mind that for her, permanent future hypothyroidism was inevitable at this point, and all such patients must have this anticipated so that once this occurs, replacement is promptly begun.
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